CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 550 enrolled
Drug / intervention
Survivorship Care Plan +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03860961
NCT03860961N/ACompleted

Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

NRG Oncology·interventional·Posted Mar 4, 2019·Updated Nov 3, 2025

In Brief

A clinical study evaluating Survivorship Care Plan and Treatment Plan for Prostate Adenocarcinoma. Completed, enrolled 550 participants across 79 sites.

Detailed Summary

This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. This is especially important for prostate cancer survivors who need routine cancer care follow-up with their radiation oncologist and also coordinated routine follow-up with their primary care provider (PCP). This is important because androgen deprivation therapy increases a patient's risk for developing diabetes, hypercholesterolemia, and cardiovascular events. Increasing the dose of survivorship may improve care and outcomes of cancer survivors than standard practices.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 4, 2019
Enrollment StartJul 26, 2019
Primary CompletionNov 14, 2024
Study CompletionSep 4, 2025
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.3 years ago

Interventions

Survivorship Care Planother

Given survivorship care plan

Treatment Planother

Given treatment plan